Company HST5040 Patients Pipeline Platform News Careers New Insights. New Hope. HemoShear Therapeutics is a clinical stage company developing new treatments for patients with rare metabolic disorders. We apply our deep understanding of complex diseases to discover breakthrough treatments for our proprietary pipeline. We also partner with biopharma companies to accelerate their drug discovery and development programs in liver diseases, gout and metabolic disorders. We are implementing a new vision for how advanced biological systems can yield new insights that improve health and quality of life for patients in need. News: First Two Patients Dosed in HERO Study of HST5040 Read More » The HemoShear Advantage The biopharmaceutical industry’s drug development success is impeded by a lack of physiological models that reflect the complexity of disease. HemoShear’s proprietary REVEAL-Tx™ platform combines biological and computational models of human disease to accelerate discovery of novel targets and successful new drug treatments. Transformative Partnerships We leverage our REVEAL-Tx™ disease modeling platform for our proprietary drug discovery programs and for exclusive collaborations with partners who want to accelerate their drug discovery initiatives. Featured News All News » Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact

Company HST5040 Patients Pipeline Platform News Careers About Us Leadership Investors Our Mission We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life. Our proprietary human disease models enable us to discover potential new drugs like HST5040 by recreating and interpreting complex human biology. We believe that no other company can match our ability to understand hepatic and vascular diseases, and we value partnerships with other companies dedicated to accelerating novel therapies for challenging diseases. Leadership Management Board of Directors Advisors James Powers Chairman and CEO Brian Wamhoff, PhD Chief Operating Officer Gerald F. Cox, M.D., Ph.D. Acting Chief Medical Officer Mavis Waller Vice President, Clinical Operations Michael Innes Chief Business Officer Brian A. Johns, PhD Chief Scientific Officer Aric Holsinger, CPA Chief Financial Officer Mark Hayes, PhD Acting Chief Regulatory Officer Paul Sartori, PhD Vice President, Organizational Development and Human Resources Mike Simmers, PhD Vice President, Operations Susan Klees Vice President, Communications Investors Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact